The overall malignancy incidence rate was largely in line with POETYK PSO-1 and PSO-2. The severity of AEs continued to be predominantly mild or moderate, and the incidence rates for non–nonmelanoma skin cancers (non-NMSCs) were not higher than observations in POETYK PSO-1 and PSO-2. The incidence rates were similar at 1 year and 2 years, except for events related to COVID-19. Over 60 weeks of follow-up in the POETYK LTE, the proportions of patients who achieved PASI 75, PASI 90, and sPGA 0/1 were similar regardless of which treatment they were receiving at Week 52. The authors also acknowledge Julie Scotto, BS, MPH, for her contributions to this analysis.